Index Entries

Mohamed Elghazal, Inas M. Alhudiri, Mohamed Said, Eiman Elhouderi, and Adam Elzagheid
January 31, 2023
Cureus
Libyan Biotechnology Research Center

"Abstract

... The US FDA issued an emergency use authorization for the Pfizer-BioNTech COVID-19 mRNA vaccine for the prevention of COVID-19 in individuals ≥ five years. However, concerns were raised after reports of new cases of myocarditis following mRNA COVID-19 vaccines, especially among adolescents and young adults. Most cases developed symptoms after receiving the second dose. Here, we present a case of a previously healthy 34-year-old male who developed sudden and severe chest pain a week after the second dose of the Pfizer-BioNTech COVID-19 mRNA vaccine...

Discussion

The patient presented with new chest pain, shortness of breath, and palpitations along with ST [ECG] abnormalities. The clinical course and investigations of our patient support the diagnosis of a probable case of acute myopericarditis according to the Centers for Disease Control and Prevention (CDC) working case definitions...

We could not identify an alternative cause for the pericarditis other than the relationship to the timing of mRNA vaccination. Acute coronary syndrome was ruled out given the absence of obstructive coronary diseases on coronary angiography...
 
Myocarditis and pericarditis are inflammatory conditions affecting the myocardium and pericardium... The most common clinical features are chest pain, dyspnea, fatigue, palpitations, syncope and cardiogenic shock."
document
adverse events,clinical cases,COVID-19,heart disorders,mRNA,vaccines